Cover Image
Market Research Report
Product code 
1045189

Global Active Pharmaceutical Ingredient (API) Market - Analysis By Drug Type (Generic, Innovative), Synthesis (Synthetic, Biotech), By Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)

Published: | Azoth Analytics | 230 Pages | Delivery time: 2-3 business days

Price

Back to Top
Global Active Pharmaceutical Ingredient (API) Market - Analysis By Drug Type (Generic, Innovative), Synthesis (Synthetic, Biotech), By Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)
Published: December 31, 2021
Azoth Analytics
Content info: 230 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Executive Summary

The global Active Pharmaceutical Ingredients (API) Market was valued at USD 179.6 Billion in the year 2020. Growth opportunities for the Active Pharmaceutical Ingredient market is attributed to the growth of the geriatric population, rising technical advancements, increasing API manufacturing facilities in the world and increasing number of research and development activities by some of the key market players in the global platform.

Additionally, growing awareness, as well as investments in the development of new drugs in the market, is pushing the number of clinical trials in the world which is driving the Active Pharmaceutical Ingredient market. With the rising prevalence of respiratory diseases due to the outbreak of COVID-19, it is expected that there will be more demand for new drugs which is likely to push the demand for API and consequently affect the Global Active Pharmaceutical Market in the world.

The biopharma companies are opting for mergers and acquisitions to gain access to new technologies, expand their market area and increase their capital for clinical trials and investments. The API market has been witnessing impressive growth over the past few years. This growth trend is projected to continue due to the increase in demand from the Asia Pacific region in the future. This is mainly driven by China, India and Japan which consist of a huge population and thereby huge incidence of infectious diseases which require medicines for treatment.

Furthermore, the rising death toll and spread of the virus prompted many pharmaceutical companies, biopharmaceutical companies and small start-ups to collaborate and bring out effective medicine to fight the same. Scientists all over the world found molecules that can effectively target COVID-19. Currently, 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. Companies monitored locally to protect the safety of study participants, staff and employees during such times.

Scope of the Report

  • The report analyses the Active Pharmaceutical Ingredients Market by Value (USD Billion)
  • The report analyses the Active Pharmaceutical Ingredients Market by Application (Oncology, Cardiology, Diabetes, Neurology, Others).
  • The report analyses the Active Pharmaceutical Ingredients Market by Drug Type (Generic API, Innovative API)
  • The report analyses the Active Pharmaceutical Ingredients Market by Synthesis (Synthetic, Biotech)
  • The Global Active Pharmaceutical Ingredients Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).
  • The Global Active Pharmaceutical Ingredients Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India).
  • The attractiveness of the market has been presented by region, by Application, by Drug Type and by Synthesis.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
  • The companies analysed in the report include Pfizer Inc., GlaxoSmithKline, AbbVie Inc., Novartis AG, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sanofi, Bristol-Myers Squibb and Boehringer Ingelheim.
  • The report presents the analysis of the Active Pharmaceutical Ingredients market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience

  • Active Pharmaceutical Ingredients Manufacturers
  • Pharmaceutical Companies
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Regulatory Authorities

Table of Contents

1. Report Scope and Methodology

  • 1.1 Scope of the Report
  • 1.2 Research Methodology
  • 1.3 Executive Summary

2. Strategic Recommendations

3. Global Active Pharmaceutical Ingredient Market: Product Outlook

4. Global Active Pharmaceutical Ingredient Market: Size and Forecast

  • 4.1 Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026

5. Global Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis

  • 5.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Application
    • 5.1.1 Oncology - Market Size and Forecast (2016-2026)
    • 5.1.2 Cardiology- Market Size and Forecast (2016-2026)
    • 5.1.3 Diabetes - Market Size and Forecast (2016-2026)
    • 5.1.4 Neurology - Market Size and Forecast (2016-2026)
    • 5.1.5 Others - Market Size and Forecast (2016-2026)
  • 5.2 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Drug Type

5.2.1  Generic API- Market Size and Forecast (2016-2026)

    • 5.2.2 Innovative API - Market Size and Forecast (2016-2026)
  • 5.3 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Synthesis
    • 5.3.1 Synthetic - Market Size and Forecast (2016-2026)
    • 5.3.2 Biotech - Market Size and Forecast (2016-2026)

6. Global Active Pharmaceutical Ingredient Market: Regional Analysis

  • 6.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Region

7. North America Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

  • 7.1 North America Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026)
  • 7.2 North America Active Pharmaceutical Ingredient Market - Prominent Companies
  • 7.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others) 
  • 7.4 Market Segmentation By Drug Type (Generic API and Innovative API) 
  • 7.5 Market Segmentation By Synthesis (Synthetic and Biotech) 
  • 7.6 North America Active Pharmaceutical Ingredient Market: Country Analysis 
  • 7.7 Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
  • 7.8 Competitive Scenario of North America Active Pharmaceutical Ingredient Market: By Country
  • 7.9 United States Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 7.10 United States Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 7.11 Canada Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 7.12 Canada Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8. Europe Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

  • 8.1 Europe Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.2 Europe Active Pharmaceutical Ingredient Market - Prominent Companies
  • 8.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others) 
  • 8.4 Market Segmentation By Drug Type (Generic API and Innovative API) 
  • 8.5 Market Segmentation By Synthesis (Synthetic and Biotech) 
  • 8.6 Europe Active Pharmaceutical Ingredient Market: Country Analysis 
  • 8.7 Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
  • 8.8 Competitive Scenario of Europe Active Pharmaceutical Ingredient Market: By Country
  • 8.9 Germany Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.10 Germany Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 8.11 United Kingdom Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.12 United Kingdom Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 8.13 France Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.14 France Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 8.15 Spain Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.16 Spain Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 8.17 Italy Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 8.18 Italy Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

9. Asia Pacific Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

  • 9.1 Asia Pacific Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 9.2 Asia Pacific Active Pharmaceutical Ingredient Market - Prominent Companies
  • 9.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others) 
  • 9.4 Market Segmentation By Drug Type (Generic API and Innovative API) 
  • 9.5 Market Segmentation By Synthesis (Synthetic and Biotech) 
  • 9.6 Asia Pacific Active Pharmaceutical Ingredient Market: Country Analysis 
  • 9.7 Market Opportunity Chart of Asia Pacific Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
  • 9.8 Competitive Scenario of Asia Pacific Active Pharmaceutical Ingredient Market: By Country
  • 9.9 China Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 9.10 China Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 9.11 Japan Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 9.12 Japan Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
  • 9.13 India Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
  • 9.14 India Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

10. Global Active Pharmaceutical Ingredient Market Dynamics

  • 10.1 Drivers
  • 10.2 Restraints
  • 10.3 Trends

11. Market Attractiveness

  • 11.1 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Application, 2026
  • 11.2 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Drug Type, 2026
  • 11.3 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Synthesis, 2026
  • 11.4 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Region, 2026

12. Competitive Landscape

  • 12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
  • 12.2 Market Share Analysis

13. Company Analysis

  • 13.1 Pfizer Inc.,
  • 13.2 GlaxoSmithKline
  • 13.3 AbbVie Inc.
  • 13.4 Novartis AG
  • 13.5 Eli Lilly and Company
  • 13.6 Merck KGaA
  • 13.7 Teva Pharmaceutical Industries Ltd.
  • 13.8 Sanofi
  • 13.9 Bristol-Myers Squibb
  • 13.10 Boehringer Ingelheim

List of Figures

List of Figures

  • Figure 1: Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 2: Percentage of API manufacturing facilities for all drugs (August 2019)
  • Figure 3: World's leading causes of death (in millions), 2019
  • Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
  • Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 6: Estimated number of new cases in 2020, worldwide, both sexes, all ages
  • Figure 7: Global Active Pharmaceutical Ingredient Market-By Application Market Share, 2020 & 2026
  • Figure 8: Global Active Pharmaceutical Ingredient Market- By Oncology, By Value (USD Billion), 2016-2026
  • Figure 9: Global Active Pharmaceutical Ingredient Market- By Cardiology, By Value (USD Billion), 2016-2026
  • Figure 10: Global Active Pharmaceutical Ingredient Market- By Diabetes, By Value (USD Billion), 2016-2026
  • Figure 11: Global Active Pharmaceutical Ingredient Market- By Neurology, By Value (USD Billion), 2016-2026
  • Figure 12: Global Active Pharmaceutical Ingredient Market- By Others, By Value (USD Billion), 2016-2026
  • Figure 13: Global Active Pharmaceutical Ingredient Market- By Drug Type Market Share, 2020 & 2026
  • Figure 14: Global Active Pharmaceutical Ingredient Market- By Generic API, By Value (USD Billion), 2016-2026
  • Figure 15: Global Active Pharmaceutical Ingredient Market- By Innovative API, By Value (USD Billion), 2016-2026
  • Figure 16: Global Active Pharmaceutical Ingredient Market- By Synthesis Market Share, 2020 & 2026
  • Figure 17: Global Active Pharmaceutical Ingredient Market- By Synthetic, By Value (USD Billion), 2016-2026
  • Figure 18: Global Active Pharmaceutical Ingredient Market- By Biotech, By Value (USD Billion), 2016-2026
  • Figure 19: Global Active Pharmaceutical Ingredient Market- By Region Market Share, 2020 & 2026
  • Figure 20: North America Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
  • Figure 22: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Figure 23: North America Urban population, 2015-2018 (In %)
  • Figure 24: North America Active Pharmaceutical Ingredient players market share (%), 2020
  • Figure 25: North America Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 26: North America Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 27: North America Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 28: Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
  • Figure 29: North America Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
  • Figure 30: United States Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 31: United State year-on-year growth of Active Pharmaceutical Ingredient (in %), (2017-2026)
  • Figure 32: United State population aged 65 and above, (in % of total population), 2016-2020
  • Figure 33: United State health expenditure (% of GDP), 2013-2018
  • Figure 34: United State Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 35: United State Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 36: United State Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 37: Canada Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 38: Canada population aged 65 and above (% of total population), 2016-2020
  • Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 40: Canada Urban population, 2015-2019 (In %)
  • Figure 41: Canada Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 42: Canada Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 43: Canada Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 44: Europe Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 45: Europe current health expenditure (% of GDP), (2014-2018)
  • Figure 46: Europe population aged 65 and above (% of total population), 2020
  • Figure 47: Europe percentage of dying between age 30 to 70 from any cardiovascular disease, cancer, diabetes and chronic respiratory disease, 2019
  • Figure 48: Europe Active Pharmaceutical Ingredient players market share (%), 2020
  • Figure 49: Europe Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 50: Europe Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 51: Europe Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 52: Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
  • Figure 53: Europe Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
  • Figure 54: Germany Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 55: Germany current health expenditure (% of GDP), (2014-2018)
  • Figure 56: Germany population aged 65 and above (% of total population), 2016-2020
  • Figure 57: Germany urban population (% of total population), 2016-2019
  • Figure 58: Germany Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 59: Germany Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 60: Germany Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 61: United Kingdom Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 62: United Kingdom current health expenditure (% of GDP), (2014-2018)
  • Figure 63: United Kingdom population aged 65 and above (% of total population), 2016-2020
  • Figure 64: United Kingdom urban population (in millions), 2016-2020
  • Figure 65: United Kingdom Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 66: United Kingdom Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 67: United Kingdom Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 68: France Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 69: France current health expenditure (% of GDP), (2014-2018)
  • Figure 70: France urban population (% of total population), 2016-2020
  • Figure 71: France population aged 65 and above (% of total population), 2016-2020
  • Figure 72: France Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 73: France Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 74: France Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 75: Spain Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 76: Spain current health expenditure (% of GDP), (2014-2018)
  • Figure 77: Spain population aged 65 and above (% of total population), 2016-2020
  • Figure 78: Spain urban population (% of total population), 2016-2020
  • Figure 79: Spain Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 80: Spain Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 81: Spain Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 82: Italy Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 83: Italy current health expenditure (% of GDP), (2014-2018)
  • Figure 84: Italy population aged 65 and above (% of total population), 2016-2020
  • Figure 85: Italy urban population (% of total population), 2016-2020
  • Figure 86: Italy Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 87: Italy Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 88: Italy Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 89: Asia Pacific Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 90: Asia Pacific urban population (% of total population), 2016-2020
  • Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 92: Asia Pacific population aged 65 years and above (% of total population), 2016-2020
  • Figure 93: Asia Pacific Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 94: Asia Pacific Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 95: Asia Pacific Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 96: Market Opportunity Chart of APAC Active Pharmaceutical Ingredient Market- By Country, By Value (Year-2026)
  • Figure 97: APAC Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
  • Figure 98: China Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 99: China total population in billions, 2016-2020
  • Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Figure 101: China export destinations of Active Pharmaceutical Ingredient, 2019
  • Figure 102: China Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 103: China Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 104: China Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 105: Japan Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 106: Japan population above 65 years (% of total population), 2016-2020
  • Figure 107: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
  • Figure 108: Japan urban population (in millions), 2016-2020
  • Figure 109: Japan Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 110: Japan Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 111: Japan Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
  • Figure 112: India Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
  • Figure 113: India Current Healthcare Expenditure (% of GDP), 2015-2018
  • Figure 114: India population (in billions), 2016-2020
  • Figure 115: India urban population (% of total population), 2015-2019
  • Figure 116: India Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
  • Figure 117: India Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
  • Figure 118: India Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Million), 2016-2026
  • Figure 119: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Application (Year-2016-2026)
  • Figure 120: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Drug Type (Year 2016-2026)
  • Figure 121: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Synthesis (Year 2016-2026)
  • Figure 122: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Region (Year 2016-2026)
  • Figure 123: Global Active Pharmaceutical Ingredient players market share (%), 2020
  • Figure 124: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
  • Figure 125: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
  • Figure 126: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
  • Figure 127: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
  • Figure 128: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
  • Figure 129: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 130: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 131: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
  • Figure 132: AbbVie Inc. Net Income (USD Million), 2016-2020
  • Figure 133: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 134: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 135: Novartis Annual Sales Revenue (USD Million), 2016-2020
  • Figure 136: Novartis Annual Net Income/Loss (USD Million), 2016-2020
  • Figure 137: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
  • Figure 138: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
  • Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
  • Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
  • Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 143: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
  • Figure 144: Merck KGaA Gross Profit, 2016-2020 (USD Million)
  • Figure 145: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 146: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 147: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
  • Figure 148: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
  • Figure 149: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
  • Figure 150: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
  • Figure 151: Sanofi Sales Revenues, 2016-2020 (USD Million)
  • Figure 152: Sanofi Gross Profit, 2016-2020 (USD Million)
  • Figure 153: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 154: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 155: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
  • Figure 156: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
  • Figure 157: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 158: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 159: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
  • Figure 160: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
  • Figure 161: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 162: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020